Akari Therapeutics Plc ADR Dossier - Source-backed chat

Akari Therapeutics Plc ADR

AKTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.24

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $9.30Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $18.1M

Enterprise Value $11.1M

Shares Outstanding 1.9M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Akari Therapeutics Plc is transitioning into a next-generation antibody-drug conjugate (ADC) developer following its strategic merger with Peak Bio in late 2024. The company's investment thesis centers on its proprietary PH1 payload platform, which targets RNA splicing via spliceosome modulation. This mechanism has demonstrated superior preclinical potency and synergistic effects when combined with KRAS inhibitors in difficult-to-treat solid tumors. However, Akari is currently a pre-revenue, pre-clinical stage biotechnology firm facing severe near-term liquidity constraints, with its cash runway extending only into June 2026. While the company has access to a $25 million equity line of credit (ELOC) and recently completed a $5.5 million private placement, the high execution risk of advancing its lead candidate, AKTX-101, toward a planned mid-2027 Phase 1 trial warrants a cautious 'Hold' recommendation until clinical validation and a stabilized cash runway are established.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$26.78

Mean target$28.39

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Akari fails to secure sufficient near-term capital, leading to severe dilution or insolvency. Technical or manufacturing delays with WuXi XDC push the AKTX-101 Phase 1 trial initiation beyond 2027. Early clinical data reveals unexpected off-target toxicities or lack of efficacy, invalidating the spliceosome-modulating payload platform.

Base CaseCentral scenario

Akari successfully completes IND-enabling studies for its lead TROP2-targeting ADC, AKTX-101, in partnership with WuXi XDC. The company leverages its $25 million ELOC and private placements to fund operations through the IND submission in late 2026/early 2027 and initiates its Phase 1 trial by mid-2027. Preclinical synergy data in KRAS-driven cancers is validated in early clinical cohorts, attracting strategic biopharma partnerships.

Bull CaseUpside scenario

Successful clinical development and validation of the proprietary PH1 RNA spliceosome-modulating payload platform, starting with positive Phase 1 data for AKTX-101 in metastatic urothelial cancer, which would validate the platform and attract lucrative biopharma licensing partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated PH1 payload platform targeting RNA splicing, designed to overcome resistance mechanisms associated with traditional microtubule or DNA-damaging payloads.
Strong preclinical data showing superior potency of AKTX-101 compared to leading TROP2 ADCs, as well as synergistic activity with KRAS inhibitors in pancreatic cancer models.
Strategic manufacturing partnership with WuXi XDC, a leading global ADC developer, to accelerate IND-enabling activities.

Key Investment Risks

Severe liquidity pressure with substantial doubt about the company's ability to continue as a going concern beyond June 2026 without additional financing.
High clinical and regulatory execution risk, as the lead asset AKTX-101 is still in preclinical development with clinical trials not expected to start until mid-2027.
Potential for significant shareholder dilution due to reliance on equity lines of credit, warrants, and private placements to fund operations.

Thesis Invalidation Triggers

Failure to submit the IND/CTA for AKTX-101 by early 2027.
Inability to secure additional funding or draw on the ELOC, resulting in insolvency or delisting from Nasdaq.
Preclinical or early clinical safety signals showing severe off-target toxicities associated with the PH1 payload.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.